Editas Medicine
Paul Wrighton has a diverse work experience spanning over several years. Paul started their career as a Clinical Pharmacology Intern at Indiana University School of Medicine in 2005. From there, they worked as a Research Assistant at Purdue University until 2008. Paul then pursued a Ph.D. in Biochemistry at the University of Wisconsin-Madison, where they served as a Graduate Student Researcher from 2008 to 2015. During this time, they focused on studying extracellular matrix signaling mechanisms related to human pluripotent stem cell self-renewal and differentiation. Following that, they joined Brigham and Women's Hospital and Harvard Medical School as a Postdoctoral Fellow from 2015 to 2021, where their research focused on mitophagy and CRISPR-mediated genetic epistasis. Currently, Paul is working at Editas Medicine, first as a Scientist II In Vivo Gene Editing/Ophthalmology from 2021 to 2022, and now as a Senior Scientist and Project Team Lead for In Vivo Gene Editing since 2023.
Paul Wrighton completed their Bachelor's Degree in Biochemistry from Purdue University from 2004 to 2008. Paul then pursued a Doctor of Philosophy (Ph.D.) in Biochemistry at the University of Wisconsin-Madison from 2008 to 2015.
This person is not in any teams
Editas Medicine
5 followers
Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.